GSA Capital Partners LLP Invests $128,000 in Axovant Sciences Ltd. (AXON)
GSA Capital Partners LLP acquired a new position in shares of Axovant Sciences Ltd. (NYSE:AXON) during the second quarter, Holdings Channel reports. The fund acquired 10,000 shares of the company’s stock, valued at approximately $128,000.
Other institutional investors have also recently added to or reduced their stakes in the company. VHCP Management II LLC purchased a new position in Axovant Sciences during the first quarter worth about $4,932,000. Quantitative Systematic Strategies LLC purchased a new position in Axovant Sciences during the second quarter worth about $682,000. Strs Ohio boosted its position in Axovant Sciences by 960.9% in the second quarter. Strs Ohio now owns 48,800 shares of the company’s stock worth $626,000 after buying an additional 44,200 shares during the last quarter. Sabby Management LLC purchased a new position in Axovant Sciences during the first quarter worth about $391,000. Finally, Alps Advisors Inc. boosted its position in Axovant Sciences by 24.9% in the second quarter. Alps Advisors Inc. now owns 139,286 shares of the company’s stock worth $1,788,000 after buying an additional 27,780 shares during the last quarter. Hedge funds and other institutional investors own 29.45% of the company’s stock.
Shares of Axovant Sciences Ltd. (NYSE:AXON) traded up 1.88% on Wednesday, hitting $14.06. 66,536 shares of the stock traded hands. Axovant Sciences Ltd. has a 52-week low of $8.86 and a 52-week high of $21.30. The stock’s market cap is $1.39 billion. The stock’s 50 day moving average price is $15.79 and its 200 day moving average price is $13.61.
Axovant Sciences (NYSE:AXON) last released its earnings results on Monday, August 15th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by $0.02. On average, equities analysts expect that Axovant Sciences Ltd. will post ($1.68) EPS for the current fiscal year.
Several equities analysts recently issued reports on AXON shares. Leerink Swann reiterated a “buy” rating on shares of Axovant Sciences in a research report on Thursday, June 30th. Zacks Investment Research cut shares of Axovant Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, August 9th. JMP Securities reiterated an “outperform” rating and set a $36.00 price target on shares of Axovant Sciences in a research report on Tuesday, August 16th. Evercore ISI restated a “buy” rating and issued a $29.00 price objective on shares of Axovant Sciences in a report on Friday, September 23rd. Finally, Robert W. Baird restated an “outperform” rating and issued a $29.00 price objective on shares of Axovant Sciences in a report on Friday, September 23rd. Two analysts have rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $25.21.
Axovant Sciences Company Profile
Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axovant Sciences Ltd. (NYSE:AXON).
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.